To prevent relapse, high risk paediatric acute lymphoblastic leukaemia (ALL) is treated very intensively. However, most patients who eventually relapse have standard or medium risk ALL with low minimal residual disease (MRD) levels. We analysed recurrent microdeletions and other clinical prognostic factors in a cohort of 475 uniformly treated non-high risk precursor B-cell ALL patients with the aim of better predicting relapse and refining risk stratification. Lower relapse-free survival at 7 years (RFS) was associated with IKZF1 intragenic deletions (P < 0Á0001); P2RY8-CRLF2 gene fusion (P < 0Á0004); Day 33 MRD>5 9 10 À5 (P < 0Á0001) and High National Cancer Institute (NCI) risk (P < 0Á0001). We created a predictive model based on a risk score (RS) for deletions, MRD and NCI risk, extending from an RS of 0 (RS0) for patients with no unfavourable factors to RS2 + for patients with 2 or 3 high risk factors. RS0, RS1, and RS2 + groups had RFS of 93%, 78% and 49%, respectively, and overall survival (OS) of 99%, 91% and 71%. The RS provided greater discrimination than MRD-based risk stratification into standard (89% RFS, 96% OS) and medium risk groups (79% RFS, 91% OS). We conclude that this RS may enable better early therapeutic stratification and thus improve cure rates for childhood ALL.
Summary
To prevent relapse, high risk paediatric acute lymphoblastic leukaemia (ALL) is treated very intensively. However, most patients who eventually relapse have standard or medium risk ALL with low minimal residual disease (MRD) levels. We analysed recurrent microdeletions and other clinical prognostic factors in a cohort of 475 uniformly treated non-high risk precursor B-cell ALL patients with the aim of better predicting relapse and refining risk stratification. Lower relapse-free survival at 7 years (RFS) was associated with IKZF1 intragenic deletions (P < 0Á0001); P2RY8-CRLF2 gene fusion (P < 0Á0004); Day 33 MRD>5 9 10 À5 (P < 0Á0001) and High National Cancer Institute (NCI) risk (P < 0Á0001). We created a predictive model based on a risk score (RS) for deletions, MRD and NCI risk, extending from an RS of 0 (RS0) for patients with no unfavourable factors to RS2 + for patients with 2 or 3 high risk factors. RS0, RS1, and RS2 + groups had RFS of 93%, 78% and 49%, respectively, and overall survival (OS) of 99%, 91% and 71%. The RS provided greater discrimination than MRD-based risk stratification into standard (89% RFS, 96% OS) and medium risk groups (79% RFS, 91% OS). We conclude that this RS may enable better early therapeutic stratification and thus improve cure rates for childhood ALL.
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ALL8 and Dutch Childhood Oncology Group (DCOG) ALL-10 ; only 11% of patients were classified as high risk and were successfully treated with more intensive chemotherapy and sometimes stem cell transplantation, increasing survival for this group from an estimated 30% to 76-82% at 5 years Pieters et al, 2016) . The greatest number of relapses consequently occurred in the large medium risk group, which represented about 60% of patients in these trials (Karsa et al, 2013) . The current AIEOP-BFM ALL 2009 trial addressed this issue by incorporating Day 15 flow cytometry of bone marrow (Basso et al, 2009 ) and defining a slow early responder B-precursor (BCP-ALL) group based on high MRD load (>5 9 10 À4 ) at Day 33 and any MRD positivity at Day 79 for risk assessment (Conter et al, 2010) , and the DCOG trial showed that MRD levels at the end of consolidation have additive predictive value , but further improvements are needed. In addition to MRD, several biological and genetic factors have been associated with risk of relapse. Historically, the National Cancer Institute (NCI) Rome risk classification of high and standard risk BCP-ALL, based on patient age and white cell count at diagnosis, has been widely used for initial stratification and to compare paediatric trial cohorts . A poorer outcome for boys was reported in some early cohorts (Shuster et al, 1998; Pui et al, 2005) and was addressed in the UKALL 2003 trial by extending the duration of maintenance therapy for males (Vora et al, 2013) . Other factors potentially contributing to relapse risk include T-ALL immunophenotype and some BCP-ALL cytogenetic groups. Both Philadelphia chromosome positive (Ph+ve ALL) with t(9;22) and KMT2A (MLL) rearrangements involving 11q23, especially t(4;11), are well recognised (Tomizawa et al, 2007) . Cytogenetic studies have identified additional small distinctive patient subsets at high relapse risk: hypodiploidy, intrachromosomal amplification of chromosome 21 (iAMP21), t(17;19) and t(8;14) Fischer et al, 2015) . Favourable outcomes are associated with the two largest BCP-ALL groups in children: ETV6-RUNX1 with t(12;21) and hyperdiploidy (>50 chromosomes) as well as TCF3-PBX1 with t(1;19). Collectively, these BCP-ALL subtypes make up about 60% of paediatric ALL cases, leaving a large group of other BCP-ALLs that lack any of these defining features.
The advent of global gene expression analysis for ALL confirmed the biological basis of these major subgroups (Yeoh et al, 2002) and identified distinct new subgroups including Philadelphia like (Ph-like) ALL (Den Boer et al, 2009 ) and the DUX4-rearranged low risk group (Lilljebjorn et al, 2016) . Ph-like ALL has similar gene expression patterns to Ph+ ALL and is associated with higher relapse rates and a variety of novel gene fusions that activate tyrosine-kinase pathways (Roberts et al, 2014) .
Another important advance has been the discovery of ALL-specific microdeletions. A large single nucleotide polymorphism (SNP) microarray study of diagnostic samples showed a mean of 4 deletions and 2Á5 gene amplifications among different ALL subtypes (Mullighan et al, 2007) . Several recurrent deletions occurred in over 20% of paediatric ALL patients (e.g. PAX5, ETV6, CDKN2A/B). Other deletions with lower incidence (5-15%) were interesting because of links to lymphoblast differentiation or tumour suppression pathways, such as IKZF1, EBF1, BTG1, RB1 (Schwab et al, 2013) . While deletions often lead to loss of function, they can also cause over-expression of adjoining genes, such as the P2RY8-CRLF2 gene fusion (PAR1 deletion) that results in higher unregulated expression of CRLF2 (Mullighan et al, 2009a; Russell et al, 2009) .
The IKZF1 gene is of particular interest because deletions are present in 55-75% of paediatric and adult Ph+ ALL and are associated with even poorer outcomes within this high risk group (Iacobucci et al, 2009) . IKZF1 deletions are present in 12-15% of non-Ph+ paediatric ALL cases, usually associated with Ph-like expression signatures and have poor clinical outcomes that are independent of MRD status (Mullighan et al, 2009b; Waanders et al, 2011; Dorge et al, 2013; van der Veer et al, 2013; Volejnikova et al, 2013) . The aim of the present study was to build upon the predictive value of MRD in paediatric ALL by the evaluation of both classical risk factors and common ALL gene microdeletions including IKZF1 in a uniformly treated trial cohort of 475 non-high risk Australian and New Zealand ALL patients, with validation in a Dutch cohort.
Patients and methods

Patients
The discovery cohort included 475 non-high risk (standard or medium risk) BCP-ALL patients aged 1-18 years with ALL consecutively enrolled on ANZCHOG ALL8 All patients considered for trial enrolment are shown in the consort diagram (Fig 1) including those who were not enrolled, refused or withdrew research consent, had other BCP-ALL Risk Score Based on Deletions, MRD and NCI Risk ª 2017 John Wiley & Sons Ltd acute leukaemia diagnoses, secondary ALL or were lost to follow-up before stratification. Patients were stratified into risk groups using MRD and other risk factors using the same guidelines as AIEOP-BFM-ALL 2000 (Flohr et al, 2008) and DCOG ALL-10 . Two patients who died in induction (prior to stratification); 67 high risk patients; 33 T-ALL cases and 30 patients without MLPA data were excluded from the discovery cohort. The high risk exclusions included poor prednisone response at Day 8; failure to remit at Day 33; Ph+ve ALL and the t(4;11) MLL translocation (KMT2A-MLLT2) or high MRD at Day 79 (>5 9 10 À4 ) (Moricke et al, 2016) .
The validation cohort was a subset of 262 Dutch medium risk BCP-ALL patients enrolled on DCOG ALL-10 in 2004-2012 and stratified in the same way . The subset was previously shown to be representative (van der Veer et al, 2013) and was analysed for clinical factors and deletions in the same way as the discovery cohort. Although stratification was the same, the therapy was different for DCOG medium risk patients, who were treated according to the Dana-Farber Cancer Institute 91-01 protocol .
Minimal Residual Disease (MRD) analysis
DNA was isolated from mononuclear cells purified from bone marrow aspirates at diagnosis, Day 33 and Day 79 and tested for MRD by Real-time Quantitative PCR (qPCR) to detect rearrangements of immunoglobulin genes and T-cell receptors (Flohr et al, 2008; Karsa et al, 2013; Sutton et al, 2015) . MRD was measured by references to standards made by serial dilution of the patient's diagnostic DNA (1 9 10 À1 , 1 9 10 À2 , 1 9 10 À3 , 5 9 10 À4 , 1 9 10 À4 , 5 9 10 À5 and 1 9 10 À5 ), with data analysis according to EuroMRD guidelines for patient stratification . For this study, Day 33 MRD data were reassessed using a higher MRD threshold of 5 9 10 À5 instead of MRD negativity. MRD < 5 9 10 À5 therefore includes patients with one or two sensitive markers giving either low non-quantitative positive results or negative results.
BCP-ALL subgroups
The BCP-ALL patients were split into 5 groups on the basis of clinical reports from accredited hospital laboratory services (following identification of T-ALL by flow cytometry-based immunophenotyping). The translocations ETV6-RUNX1 and TCF3-PBX1 were identified by reverse-transcription-PCR or fluorescence in situ hybridisation (FISH) and patients with hyperdiploidy >50 were identified by karyotyping or FISH.
Other identified cytogenetic aberrations were grouped as BCP-other lesions and those with normal and incomplete results were designated BCP-no lesion ID.
Multiplexed Ligation Probe Amplification (MLPA) analysis
DNA obtained at diagnosis was analysed using a SALSA MLPA P335 ALL-IKZF1 A4 or B1 kit (MRC-Holland, Amsterdam, the Netherlands) with data analysis by Coffalyser software (https://www.mlpa.com/WebForms/WebFormMain.a spx) according to manufacturer's instructions. Gene copy number status was determined for several exons at 7 gene loci -CDKN2A/B, EBF1, ETV6, IKZF1, PAX5, RB1 and P2RY8-CRLF2 (PAR1). At least two exons (i.e. 2 ligated probe regions) were required for calling deletions except for the CDKN2A/B loci which had only 3 probes and the P2RY8-CRLF2 (PAR1) deletion that was defined by loss of CSF2RA and IL3RA and retention of CRLF2 and SHOX probe sequences.
Statistics
Event-free survival (EFS) was defined as time from diagnosis to first event (relapse, second malignancy excluding skin cancer, or death from any cause) or to last follow-up in clinic. Relapse-free Survival (RFS) was the time from remission to relapse or last follow-up in clinic, with 8 patients censored at the time of second malignancy and 5 for death in remission. Overall survival (OS) was defined as lapsed time between date of diagnosis to last follow-up date in clinic or death from any cause. The dataset for the discovery cohort was closed on 1 July 2016 and median follow-up for uncensored (surviving) patients was 7Á6 years. Kaplan-Meier Survival curves, Log-rank (Mantel-Cox) and Hazard Ratio (MantelHaenszel) tests were performed using GraphPad Prism (https://www.graghpad.com). Cox proportional hazard models with multiple variables were performed using the forward method in Medcalc version 12 1Á3Á0 (https://www.medcalc. org) and Cumulative Incidence of Relapse (CIR) and Grey probability of differences were estimated by R version 3Á0Á1 (package-cmprsk; https://CRAN.R-project.org/packa ge=cmprsk).
Results
Analysis of risk factors predicting relapse in non-high risk ALL
Clinical and genetic risk factors were evaluated in 475 uniformly treated non-high risk BCP-ALL patients consecutively enrolled on ANZCHOG ALL8 from 2002-2011 with the aim of identifying factors predictive of the 80 relapses that occurred in either medium (n = 66) or standard risk (n = 14) groups. As shown in Table I , univariate analyses revealed a significant predictive value for relapse of 9 different factors. Patients with Day 33 MRD >5 9 10 À5 had 28% relapses compared to 14% incidence of relapse for patients with Day 33 MRD <5 9 10 À5 (MRD negative and nonquantifiable low levels). This threshold was previously shown to provide better discrimination of at risk patients (Karsa et al, 2013) . The classic risk factors of age >10 years and white cell count >50 9 10 9 /l were combined in Table I as NCI High risk with 33% relapses compared to 11% for NCI standard risk. The 80 relapses occurring in BCP-ALL patients were unevenly distributed between different cytogenetic groups with fewer relapses in patients with ETV6-RUNX1 (n = 12, 10% P < 0Á01) and more in cases with BCP-other lesions (n = 27, 29%, P < 0Á001). The lower half of Table I shows the outcomes according to the presence of microdeletions in selected exons of CDKN2A/ B, EBF1, ETV6, IKZF1, PAX5, RB1 and P2RY8-CRLF2 genes, detected by MLPA analysis. At least one deletion at these 7 loci was detected in 66% of patients and in 71% of patients who relapsed. The deletions with significant effects on RFS, EFS and OS were P2RY8-CRLF2, IKZF1 and RB1 (Fig 2, Table I ), while BTG1, EBF1, CDKN2A/B, PAX5 and ETV6 had less impact. Almost all deletions were heterozygous losses, except for the CDKN2A/B locus, where homozygous loss was common (n = 79/) with a trend to lower OS (P < 0Á05). Homozygous loss of ETV6 (ETV6-HO) was rare (n = 8, 1Á7%), however, 6 of these patients relapsed (P < 0Á0001, Table I ). Two of the ETV6-HO patients had iAMP21. In contrast, heterozygous ETV6 loss, which often coincided with the presence of ETV6-RUNX1, was associated with fewer relapses and a better OS (P < 0Á01) (Fig 2D, Table II) .
We investigated whether combinations of deletions influenced the risk of relapse (Table S1, Figure S1 ) by examining the 150 patients with 2-5 deletions and the 162 patients with only a single deletion. The percentage of relapses in patients with DIKZF1 alone was 45% (n = 11 patients) compared to 38% (n = 39) for patients with DIKZF1 combinations. In contrast, the relapse rate for DCDKN2A/B alone was 14% vs. DIKZF1 was 38%; P2RY8-CRLF2 28%; DRB1 50%; DPAX5 21% and DETV6 HET only 6%). Single deletions of P2RY8-CRLF2, EBF1, BTG1 and ETV6-HO were all rare (n = 2, 3, 2, 0) with no relapses.
Combination of risk factors for RFS to improve predictive value
The 9 significant factors in Table I were entered into a Cox proportional-hazards regression model for RFS which identified 5 independent factors (Table II) . Day 33 MRD >5 9 10 À5 , NCI Risk and three deletions (IKZF1, P2RY8-CRLF2 and ETV6 homozygous loss) were included in the model. Patient gender, ETV6-RUNX1, other BCP-ALL and RB1 deletion were not independent predictors of prognosis in this multivariate analysis. We next sought to analyse these independent risk factors with the aim of identifying both a group at high-risk of relapse, which need more effective therapy, and a group in whom therapy might be able to be reduced. In considering The total numbers of patients and number and % who relapsed are shown for each group. P values were calculated for pairs of Cumulative incidence of relapse values using the modified Chi test according to Grey. The significant variables used in the Cox analysis (Table II) . Event-free survival and overall survival estimates were compared using Mantel-Cox log rank test. The T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell precursor (BCP) subtypes were compared with the rest of the patients in the cohort. NS, not significant; D: deletion; present, either homozygous or heterozygous deletion; absent, normal copy number. Patients with a deletion were compared with the absent group the deletions, we combined patients with either IKZF1 or P2RY8-CRLF2 deletions or both (n = 5) into a high-risk deletion group (n = 72) designated HRdels (Fig 3) . We chose not to include the ETV6-HO deletion because the observation is unvalidated and 2 of the 8 rare patients had iAMP21 (now considered high risk). The HRdel group accounted for 27 of the 80 relapses (34%) occurring in the 475 patients (RFS 59% at 7 years) (Fig 3A) . HRdel was a more effective discriminator of relapse than Day 33 MRD >5 9 10 À5 and NCI high risk (Fig 3 B,C) . We investigated whether inclusion of HRdels results would enhance MRD stratification of non-high risk BCP-ALL. The results in Fig 4A clearly show the benefit this combination. One third of patients with low MRD (<5 9 10 À5 ) and HRdels relapsed (65% RFS) and a half of patients with both moderate MRD (>5 9 10 À5 at Day 33; <5 9 10 À4 at Day
79) and HRdels relapsed (RFS 48%). Interestingly, HRdels results also improved stratification by NCI risk group (Fig 4B). Patients with either high NCI risk or HRdels had intermediate outcomes (RFS 73%
) and those with both had an RFS of 44%. Finally, the paired combination of moderate MRD and high NCI criteria were also effective with an RFS of 54% (Fig 4C) . The 3 plots in Fig 4 collectively suggested that all 3 factors could be combined in a predictive score for children with non-high risk BCP-ALL.
Risk score analysis
Patients were scored by assigning one point for each of the 3 independent high risk factors (Day 33 MRD >5 9 10 À5 , NCI High risk and the presence of one or two HRDels (Fig 5) . Thus, Risk Score zero (RS0) applied to patients who were NCI standard risk, with Day 33 MRD <5 9 10 À5 and without IKZF1 or P2RY8-CRLF2 deletions. RS0 made up 50% of the cohort with 93% RFS and 99% OS at 7 years, which compares favourably with the original (iBFM-defined) standard risk group with 89% RFS and 96% OS (Fig 5 A,B) . RS1 was the second largest group (37% of non-high risk BCP-ALL) and had near identical outcomes to the original iBFM medium risk patients. The 62 RS2 + patients had a RFS of 49%, and represented 13% of the non-high risk cohort. Interestingly, the RS2 + patients had an EFS of 44% and OS of 71% (Fig 5 C,  D) . The defining risk characteristics, relapses, transplants and deaths for individual RS2 + patients are shown in Table S2 . The RS2 + score identified 29/80 (36%) of relapses and predicted 17/34 (50%) of deaths. The 17 survivors were rescued either by chemotherapy alone (n = 5) or chemotherapy and allogeneic bone marrow transplant (n = 12). Minimal residual disease at Day 33 > 5 9 10
A Cox proportional hazard regression model was fitted for 475 patients using the forward method with 9 patient variables entered (P < 0Á05) shown in grey in Table I . They included the 5 factors listed above and male, ETV6-RUNX1, B-cell precursor (BCP) -Other lesions and RB1 deletion (these 4 variables were removed by the model (P > 0Á1).
Confirmation of risk score in different subsets of patients
The RS was based on analyses of all 475 non-high risk BCP-ALL ANZCHOG ALL8 patients with deletion data. In order to test its robustness, we analysed the standard and medium risk patients separately for RS (Fig 6A,B) . The data confirmed that the RS applies to both groups. The RS2 + standard risk group was small, but all 5 of them relapsed. Given the differences in relapse rates observed between the groups (Table I) , we also examined the BCP-ALL subtypes and gender of patients in relation to high RS (Fig 6 C,D ,E,F and Table S2 ). While RS2 + patients made up 13% of the whole cohort, there were only two with ETV6-RUNX1 (one of whom relapsed) and one with TCF3-PBX1 who died in remission. Amongst hyperdiploid-ALL patients, 9% were RS2 + (including 7 with high risk IKZF1 deletions) and 30% of BCP-other ALL patients were RS2 + . The outcomes by RS group were very similar for these 2 subsets (Fig 6 C,  D) , so their difference in relapse rate (19% CIR for hyperdiploidy>50 vs. 29% CIR for BCP-other) is explained by their RS factors (MRD, age, white cell count, IKZF1 and P2RY8-CRLF2). In contrast, the proportions of boys in the 3 RS groups (13% RS2 + , 38% and 49%) were very similar to girls (13%, 36% and 51%) and the higher relapse rate in boys versus girls (21% vs. 14% CIR, P < 0Á05, Table I ) is reflected in a trend for poorer RFS for males in each of the RS groups (Fig 6E,F) .
Validation of Risk Score in an independent cohort
To validate our RS, we chose a set of medium risk BCP-ALL patients from the DCOG ALL10 cohort with MRD and microdeletion data (n = 262). Although the DCOG patients were stratified in the same way, they received different therapy. When the same risk criteria were applied to this validation group, the RS value provided good discrimination of patients with different outcomes (Fig 7) . In the discovery and validation cohort, RS2 + patients represented 17% and 19% of medium risk patients and scoring identified 36% and 39% of medium risk relapses, respectively. Interestingly, the outcomes were better overall, particularly for the RS2 + patients, in the validation set treated with DCOG10 compared to discovery medium risk group treated with ANZCHOG ALL8 (78% vs. 55% RFS for RS2 + ) (Fig 7) .
Discussion
The majority of relapses in the ANZCHOG ALL8 trial for newly diagnosed ALL in children occurred in the large medium risk group -a finding consistent with the results of related frontline trials with the same MRD stratification strategy -AIEOP-BFM ALL 2000 and DCOG ALL10 (Conter et al, 2010; Schrappe et al, 2011; Pieters et al, 2016) . While risk assignment could be improved by changing MRD thresholds (Basso et al, 2009; Conter et al, 2010; Schrappe et al, 2011; Karsa et al, 2013) , it was also apparent that other factors contribute to patient prognosis. In this paper, we focussed on clinical information that was already available or could be readily obtained by affordable, robust diagnostic tests, to detect common ALL microdeletions. Our results clearly confirm the prognostic value of IKZF1 deletions and the P2RY8-CRLF2 fusion in ANZCHOG ALL8 patients. In a multivariate regression analysis, the independent risk factors for relapse were these same two gene deletions, NCI risk (age and white cell count) and Day 33 MRD >5 9 10 À5 . We have created an effective risk scoring system that combines these data and have validated it in a contemporaneous Dutch cohort. Our findings are in keeping with earlier studies that established the general principle that leukaemia biology is an important factor in determining risk of relapse. The poor prognosis associated with IKZF1 deletions has been well established (Mullighan et al, 2009b; Kuiper et al, 2010; Waanders et al, 2011; Palmi et al, 2012; Dorge et al, 2013; van der Veer et al, 2013; Volejnikova et al, 2013; Olsson et al, 2014; Boer et al, 2016) In addition, based on these data, a combination of MRD and IKZF1 deletions is being used to stratify patients in the DCOG-11 trial and therapy is extended to 3 years with additional maintenance treatment for IKZF1 deleted cases .
We found higher relapse rates for patients with the P2RY8-CRLF2 deletion, confirming results from other cohorts (Cario et al, 2010; Harvey et al, 2010; Attarbaschi et al, 2012) . Interestingly, two groups have reported that higher relapses were associated with the P2RY8-CRLF2 gene fusion itself and not with higher CRLF2 expression (Cario et al, 2010; Palmi et al, 2012) . Other studies have shown important effects of Ph-like expression or specific-associated fusions, microdeletions and/or cytogenetics (Marks et al, Chilton et al, 2014; Boer et al, 2016) . In an investigation using the same MRD and MLPA methodologies to our study , the prognostic value of both deletions and cytogenetics was shown for the UKALL 2003 cohort, which notably already used a stringent early MRD threshold (1x10 -4 at Day 28).
Aberrations at chromosome 9p21 are well known in ALL and encompass several genes of interest. The CDKN2A/B deletions cause (partial) loss of two tumour suppressors (previously known as INK4A and ARF) and this loss is associated with greater therapy resistance in Ph+ve ALL (Mullighan et al, 2008) . We found a 17% incidence of homozygous CDKN2A/B deletions, consistent with a previous report of approximately 20% in BCP-ALL (Bertin et al, 2003) and a trend to poorer OS (P < 0Á05). An analysis of matched diagnosis-relapse pairs showed that CDKN2A, PAX5 and EBF1 recurrent deletions at diagnosis were less likely to be retained at relapse than IKZF1 deletions, and suggested that they are secondary events not often retained in the resistant clone from which the disease redevelops (Kuiper et al, 2010) . Some of our other findings would benefit from further investigation of larger groups. Firstly, our observation that 6/ 8 patients with homozygous deletion of ETV6 relapsed is interesting, although it may reflect underlying biology such as ETV6-ABL1, ETV6-PDGFRB or iAMP21, which are known high risk factors (Roberts et al, 2012) . Secondly, the trend observed for more relapses (30%) in patients with deletions in BTG1 (BTG anti-proliferation factor 1) is worthy of note because BTG1 loss has been associated with both steroid resistance and poorer prognosis in the ALLR3 trial for relapsed paediatric ALL (Irving et al, 2016) . In addition, BTG1 deletions appear to accentuate the poor outcome of newly diagnosed patients with IKZF1 deletions (Scheijen et al, 2017) . Finally, the higher relapse rate (33%) for 40 patients with RB1 deletions is also interesting. Heterozygous loss of RB1 frequently occurred with another deletion (IKZF1, P2RY6-CRLF2 or CDKN2A/B) but failed to reach significance in our multivariate analysis. The UK group detected RB1 deletions in cases with chromosomal 13q aberrations and iAMP21 ALL, suggesting that this tumour suppressor deserves further investigation in ALL (Schwab et al, 2013) .
The biology and genetics of ALL is clearly important and the broad cytogenetic groups and gene deletions analysed in this study can only explain some variation in risk. It is both interesting and challenging that, even with two classic risk factors and two deletions, we were unable to predict 100% of relapses. This study lacked an evaluation of mutations that can contribute to relapse in some cases (Beldjord et al, 2014; Hunger & Mullighan, 2015) , and of expression patterns and novel fusions (Roberts et al, 2014) that are becoming increasingly important to our understanding of ALL.
Nevertheless, it was clear that IKZF1 and CRLF2 deletions add substantially to risk stratification and that use of HRdels, identified by MLPA or alternative methods, could be easily implemented by any ALL trial group that already uses MRD stratification. The alternate combination of HR deletions and High NCI group was also effective, and likely to be useful in trials not using MRD stratification because of cost, although with the caveat that our score was developed for non-high risk BCP-ALL and we had already used MRD response to identify our high-risk patients.
Our simple Risk Score (RS based on HRDels, NCI risk and Day 33 MRD >5 9 10 À5 ) was effective in identifying a new small set of high risk patients (RS2 + 13% of the cohort), encompassing 32% of the relapses and 50% of the deaths. It was robust in predicting risk of relapses in the major subgroups with relapses -B-Other patients, hyperdiploid-ALL, boys and girls -and was a major improvement compared to the trials stratification into standard and medium risk groups. Finally, we have validated the utility of this RS in an independent set of patients, the medium risk cohort of DCOG ALL-10 that was treated using a different treatment regime by the Dutch Oncology group .
Our RS system could readily be applied to improve stratification of patients in future trials. It is flexible, so that additional specific or rare risk factors can be added to improve the score in future (e.g. Ph-like fusion transcripts and TP53 mutations). In its current form, RS2 + patients (who have 2 or 3 risk factors) made up 13% of non-high risk patients and therapy escalation is warranted to improve their RFS of 49%. Higher intensity chemotherapy and allogeneic stem cell transplantation in first remission were effective in the HR patients enrolled on ANZCHOG ALL8 Sutton et al, 2015) . Another option is to use the extended asparaginase and dexamethasone/vincristine pulses during maintenance as per the DCOG validation cohort, since the DCOG RS2 + group had 78% RFS, suggesting this therapy can prevent some RS2 + relapses. In contrast, the RS0 group encompassed 50% of patients and had 99% OS, suggesting that they are suitable for the evaluation of less toxic therapy combinations in future trials.
We conclude that the incorporation of other risk factors and/or use of the RS system will enable better identification of newly diagnosed ALL patients who may have therapy reduced, and of those high-risk patients in need of early intensification of therapy to prevent relapse. 
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